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The two most desirable properties of any pharmaceutical
preparation must surely be selectivity and potency. Any
agent that has such properties will by definition have a high
therapeutic index, that is the effective dose will be orders of
magnitude below the toxic one. In many areas of medicine,
the drugs used have these desirable properties and many
conditions are successfully treated. One is frequently asked
by the lay public why this success is not generally seen in
treating the majority of common solid cancers. There is no
short simple answer to this question. In two recent reviews
(Double & Bibby, 1989; Phillips et al., 1990) we have been
critical of past and present approaches used to select anti-
cancer drugs for clinical trials. However, if one takes a closer
look at the data produced by screening systems in the past, it
is quite clear that models like the L1210 and P388 murine
leukaemias identified many agents with 'desirable' properties
in that they were selective and potent and many exhibited
broad spectrum activity on other model systems. One can
only conclude that as these 'desirable' properties, with the
possible exception of the leukaemias and lymphomas (Mar-
soni et al., 1987), produced very limited clinical activity, there
must be serious flaws in the way in which anticancer agents
were developed.
In our first review we argued the case that the so-called
desirable drug properties would have appeared less so if they
had been determined using more realistic animal model
systems. That is to say, if agents identified in murine leu-
kaemias were tested against murine solid tumours their poor
selectivity and their low therapeutic indices would have been
apparent. Today it is reasonably accepted that solid tumours
(human and mouse) are more resistant to standard cytotoxic
agents than the leukaemias, indeed many mechanisms have
been identified to explain this difference at the biochemical
level. It was undoubtedly this realisation that prompted the
NCI to radically alter its screening programme (Alley et al.,
1988). The new screening programme differs radically from
previous screening systems in that it based on in vitro sen-
sitivity and that all the major clinical forms of human
cancers are represented by panels of well characterised
human tumour cell lines (Boyd, 1989). Many of the technical
criticisms of this approach have been discussed in the second
review and detailed repetition is not justified. However, there
are some more philosophical issues on drug discovery and
drug design that are worth consideration such as selectivity,
potency and characterisation of model systems.
If an agent is selective by implication there must be a
significant difference between the 'target cell' and other cells.
So far the differences identified between tumour cells and
normal cells have been of a rather qualitative nature and
have not yet resulted in any successful 'magic bullets'. It is to
be hoped that the molecular biologists will eventually identify
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more quantitative differences that can be exploited. However
I am a little concerned that much of the current work in this
area seems to be addressing problems associated with proli-
feration, a property common to all cells and may be over-
looking the fact that the 'antiproliferative' agents so far
identified have not been selective. I am also rather concerned
that some of this work is being carried out using model
systems that may have little relevance to human cancer. In
terms of selectivity it is also important to realise 'new' agents
may produce toxicities that are very different from those
produced by cytotoxics and it is quite conceivable that a
tissue oforigin could be targeted along with the tumour. This
criticism also applies to a certain extent to agents identified
in the NCI screen as this is specifically designed to identify
compounds with a high specificity towards particular cell
lines. It is to be hoped that compounds identified as positive
in the in vitro screen will reveal any potential toxicities in the
subsequent in vivo evaluation against the relevant tumour
types that are a part of development strategy (Boyd, 1989)
rather than in the disease orientated phase 1-11 clinical
trials.
Although perhaps not strictly within the brief given by the
title in terms of finding new agents the ADEPT (Antibody
Directed Enzyme Prodrug Therapy) programme (Connors,
1990) is an attempt to make better use of existing cytotoxic
moieties. Immuno-histochemistry and other immuno-imaging
techniques have shown that in some cases tumours can be
located with a high degree ofprecision. This coupled with the
fact that there is a vast number of enzymes with unique
substrate specificity opens up almost endless opportunities
for treatment. However the ultimate success of the pro-
gramme will depend on the identification of antibodies that
bind selectivity to tumour cells and not to the cells of origin.
The use of appropriate model systems will also be crucial to
success of this programme.
The importance of potency as a desirable feature of a drug
is perhaps obvious, however in terms of drug discovery, in
vitro potency implies good drug penetration into cells and
good aqueous solubility. These properties may considerably
reduce the formulation difficulties that have slowed the pro-
gression of some compounds. It must also be pointed out
that the lack of in vitro potency does not mean lack of in vivo
activity and compounds requiring bioactivation or host
interactions will not be identified, a point I will return to
later. However I have long felt that in the past drug deve-
lopers have perhaps overlooked the importance of formu-
lation. A well formulated drug will have good bioavailability
and biodistribution; these properties can fundamentally effect
pharmacological action. Having been involved in this field
for over 25 years, I can well remember making suspensions
of 'brick dust' in arachis oil prior to i.p. administration,
frequently to ascitic tumours. It is perhaps not surprising
that antitumour activity identified in this way showed little
selectivity in clinical trials. However I do appreciate the
problems of my colleagues in medicinal chemistry and accept
that in order to identify antitumour activity in a lead com-
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pound from a 'rationally designed drug programme' it still
may be necessary to follow the old approaches. One would
then hope that the analogue development on compounds
identified in this way would be pursued with formulation in
mind.
Undoubtedly a key feature in the success of the drug
development and discovery programme will be use of appro-
priate model systems. It is important to realise that many of
the current model systems may be of little use in evaluating
novel structures with unknown mechanisms of action or
agents that may act through some host mediated mechanism.
A model system must reflect a specific clinical situation and
clearly as the experience with flavone acetic acid (FAA)
shows the spectacular activity in many 'well established'
laboratory models was not seen in the clinic (Bibby, 1991).
From our own work in anticancer drug development our
experience with FAA has alerted our awareness to many
potential deficiencies in the current laboratory models partic-
ularly when dealing with agents that may act through some
indirect mechanism. In this context indirectly acting agents
would not just include 'biological response modifiers' but
those requiring host or tumour activation as well. It may well
be that with agents like biological response modifiers or
growth factors that there are no appropriate laboratory
models and clinical trials have to be based on 'reasoned
concepts' and conducted accordingly. At the end of the day
the same approach may still have to be made with 'hormone
dependant' tumours. Undoubtedly there are reasonable bio-
chemical and animal tumour models for antioestrogen and
aromatase inhibitors which are very useful for determining
basic concepts in laboratory models. However the clinical
impact in terms of long term survivors for such 'hormone'
based drug development strategies is still disappointing.
Bio-reductive agents are currently receiving considerable
attention. These are being specifically designed to eliminate
hypoxic fractions in solid tumours that are frequently refrac-
tory to both radiation and cytotoxic therapy. The laboratory
development and clinical success of these agents will depend
to a large extent on the use of appropriate model systems.
The existence of tumour hypoxia and consequent reducing
environment provides the potential for real 'selectivity' to be
designed into the molecule. This bio-reductive environment
will not be found in many of the conventional screening
systems. It is therefore important that the model systems
used are appropriately set up and characterised. In this con-
text, the in vitro system used by the group at Harwell (Strat-
ford et al., 1990) has much to commend it and they have
demonstrated considerable hypoxic cell selectivity in several
lead compounds. Their in vitro 'screening system' is further
complemented by in vivo models where this selectivity can be
confirmed following the elimination of the oxic fraction by
local radiation. Another aspect of the drug development
programme is being built round reductive enzyme profiles
associated with tumour hypoxia. DT-diaphorase has been
associated with the selectivity seen with the EORTC lead
compound E09 (Workman et al., 1990). Furthermore there
is a strong case that such reductases should be the targets for
drug design. There is evidence to suggest that even transient
tumour hypoxia induced by vaso manipulations may produce
a switch cellular reductive metabolism and produce selectivity
(Sleigh et al., 1991). Although I have stressed the importance
of appropriate models for developing new drugs it is impor-
tant to appreciate that clinical trials will also have to be
appropriately designed to evaluate specific approaches. This
will be particularly true with bio-reductives for as single
agents even if the hypoxic fraction was eliminated it is
unlikely that this would produce a measurable antitumour
response. Phase II/III trials would have to be in combination
with other modalities that would active against the oxic or
well vascularised areas of the tumour and an additive effect
could be measured.
In the title I posed the question of whether we are doing
the right things to find the right compounds. The answer is
probably unknown, as only time will tell. It would also be
arrogant to suggest that there was a right or wrong way of
anticancer drug development. However it would be rather
remiss of me not to use this opportunity of 'flag waving' for
my colleagues in the EORTC Screening and Pharmacology
Group (SPG) and our colleagues from the other basic
research groups and the New Drug Development Office.
Within the SPG we have a good balance of chemists and
biologists and many of the points I have raised earlier are
being addressed by the group. We are particularly concerned
with the use of appropriate model systems and the need to
involve new areas of chemistry and molecular biology to
pursue our objectives of rational anticancer drug develop-
ment.
To conclude, although I have been slightly critical of the
NCI approach to drug discovery it does have the potential to
rapidly identify new agents with perhaps novel mechanisms.
There is a good working relationship between the NCI,
EORTC and the CRC that would ensure that agents identi-
fied in the primary screen are rapidly progressed to clinical
trials, and furthermore novel active agents would then
become the objects of in depth studies that may allow us to
identify new targets and mechanisms. I am hopeful that this
approach will result in the development of selective and
potent anticancer agents.
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